veliparib (ABT-888) / AbbVie  >>  Phase 3
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
veliparib (ABT-888) / AbbVie
BrighTNess, NCT02032277 / 2013-002377-21: A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

Checkmark BRIGHTNESS trial in neo-adjuvant triple negative breast cancer
Apr 2017 - Apr 2017: BRIGHTNESS trial in neo-adjuvant triple negative breast cancer
Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
3
634
Europe, Canada, US, RoW
Cyclophosphamide, Placebo, Doxorubicin, Paclitaxel, Carboplatin, Veliparib, ABT-888
AbbVie, German Breast Group, NSABP Foundation Inc, Grupo Español de Investigación del Cáncer de Mama, US Oncology Research
Triple Negative Breast Cancer
03/16
11/20
NCT02106546 / 2013-005020-42: Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Completed
3
970
Europe, Canada, US, RoW
Carboplatin, Veliparib, ABT-888, Paclitaxel, Placebo to veliparib
AbbVie
Squamous Non-Small Cell Lung Cancer
01/17
11/19
BROCADE3, NCT02163694 / 2014-000345-70: A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Checkmark From BROCADE3 trial in combination with carboplatin & paclitaxel in BRCA-mutated advanced breast cancer
Aug 2020 - Aug 2020: From BROCADE3 trial in combination with carboplatin & paclitaxel in BRCA-mutated advanced breast cancer
Checkmark Data from BROCADE3 trial in 1-3L BRCA breast cancer
Oct 2019 - Oct 2019: Data from BROCADE3 trial in 1-3L BRCA breast cancer
Completed
3
513
Europe, Canada, US, RoW
Veliparib Placebo, Veliparib, ABT-888, Carboplatin, Paclitaxel
AbbVie
Metastatic Breast Cancer
04/19
01/24
VELIA, NCT02470585 / 2014-005070-11: Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Checkmark From VELIA trial for previously untreated stages III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer
Jan 2020 - Jan 2020: From VELIA trial for previously untreated stages III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer
Terminated
3
1140
Europe, Japan, US, RoW
Veliparib, ABT-888, Paclitaxel, Carboplatin, Placebo to Veliparib
AbbVie, Gynecologic Oncology Group;Australia New Zealand Gynaecological Oncology Group
Ovarian Cancer, Ovarian Neoplasm
05/19
10/23
NCT02264990 / 2014-002565-30: Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

Hourglass Jul 2019 - Sep 2019 : Data from trial for non-squamous NSCLC
Completed
3
595
Europe, Canada, Japan, US, RoW
Paclitaxel, Carboplatin, Cisplatin, Veliparib, ABT-888, Pemetrexed, Alimta
AbbVie
Non-squamous Non-small Cell Lung Cancer
11/19
02/20
A071102, NCT02152982: Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Active, not recruiting
2/3
447
US
Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Veliparib, ABT 888, ABT-888, ABT888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma
12/21
12/25

Download Options